AACR 2023: Discovery of BCG033, A Novel Anti-PTK7 x TROP2 Bispecific Antibody-Drug Conjugate with Promising Efficacy Against Triple-Negative Breast Cancer
Conclusions
- BCG033 is a novel and fully human bispecific PTK7 and TROP2 antibody-drug conjugate generated from the RenLite® platform.
- Cytotoxicity assays and internalization assays indicate a potentially better tumor cell selectivity of BCG003 compared to the parental anti-TROP2 monoclonal. BCG003 induced potent cell killing of PTK7/TROP2 co-expressing tumor cells.
- BCG033 candidates showed potent anti-tumor activity in both TNBC CDX and BC PDX models, indicating that BCG033 has strong therapeutic potential in TNBC and other PTK7/TROP2 co-expressing cancers.
- PTK7/TROP2 is co-expressed in a variety of solid tumors, suggesting multiple potential indications for BCG033.
